Morgan Stanley upgrades Haleon on sector leading exposure to defensive product categories.
Analysts at Morgan Stanley upgraded their recommendation for shares of consumer healthcare outfit Haleon.
Haleon
09 May 2025 20:55:05
Source: Sharecast
To back up their move, they pointed to the company's leading exposure in defensive categories, as well as the now greater clarity on margin expansion.
Hence, the analysts said that they now saw a path towards a high single digit compound annual growth rate for its earnings per share between 2026-30 - which was ahead of its sector peers.
Combined with the uncertain macroeconomic backdrop, they judged the company's shares to be an "attractive defensive play".
They also hiked their target price for the shares from 400.0p to 425.0p.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
